IRVINE, Calif., Feb. 29 NuRx PharmaceuticalsInc. (OTC Bulletin Board: NURX) today announced it has retained Russo PartnersLLC for the provision of investor relations and corporate communicationscounsel.
The healthcare communications firm will implement a comprehensive programthat consists of investor targeting, the scheduling of presentations atindustry conferences, media relations and other corporate visibilityinitiatives. Russo Partners will collaborate with OTC Communications, adivision of Rx Communications Group LLC, on the implementation of some programtactics.
"We are in a unique position with a clinical-stage pipeline and largeportfolio of retinoid and rexinoid compounds that were developed over a numberof years by world-class researchers who have joined the NuRx scientific team,"said Harin Padma-Nathan, M.D., NuRx's president and CEO. "We intend toinitiate three to four clinical trials this year. Therefore, the need tosupport the associated news flow prompted us to select Russo Partners todevelop and lead our communications efforts with Wall Street and thebiotech/pharmaceuticals community. The firm has the healthcare industryexpertise, senior-level talent and investor and media relationships that werecritical to our selection of a communications partner."
Russo Partners LLC, formerly Noonan Russo, provides strategiccommunications services to emerging healthcare - biotech, medical device,diagnostics and healthcare services - companies worldwide. Headquartered inNew York City, the firm has a West Coast office in San Diego and an affiliatedoffice in London. For more information, visit www.russopartnersllc.com.
NuRx Pharmaceuticals Inc. is an emerging biotech company focused on thedevelopment of retinoid and rexinoid compounds with application in oncology(treatment, prevention and adjunctive supportive therapy), the treatment ofdiabetes, the regulation of lipid metabolism and bone metabolism and repair.The company's lead compounds are (1) NRX4204, a highly specific,first-in-class rexinoid agonist that is targeted for development in non-smallcell lung carcinoma and breast cancer; (2) NRX5183, a RAR alpha subtype-specific agonist for the treatment of acute leukemia; and (3) NRX4310, afunction selective receptor modulator for the treatment and prevention ofchemotherapy-induced neutropenia. Located in Irvine, Calif., NuRx has atechnology and IP platform that includes a library of nearly 6,000 compoundssupported by 230 issued U.S. and international patents and more than 80additional patents in application. For more information, visitwww.nurxpharmaceutical.com.
The above information contains information relating to the Company that isbased on the beliefs of the Company and/or its management as well asassumptions made by and information currently available to the Company or itsmanagement. The Company, from time to time, may discuss forward-lookinginformation. Except for the historical information contained in this newsrelease, all forward-looking statements are predictions by the Company'smanagement and are subject to various risks and uncertainties that may causeresults to differ from management's current expectations. Such factors includethe fact that the Company is engaged in early stage research and does notexpect to obtain any revenues for several years and other risks as detailedfrom time to time in the Company's registration statement and reports andfilings with the Securities and Exchange Commission. All forward-lookingstatements, if any, in this news release represent the Company's judgment asof the date of this news release. The Company disclaims, however, any intentor obligation to update forward-looking statements.CONTACTS: Media David Schull (212) 845-4271 [email protected]
Investors Rhonda Chiger (917) 322-2569